Navigation Links
Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast
Date:2/25/2008

MOUNTAIN VIEW, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Omnicell, Inc. (Nasdaq: OMCL), a leading provider of system solutions to acute healthcare facilities, announced today that its Board of Directors has approved the repurchase of an aggregate of up to $40 million of its Common Stock over the next 12 months. The Company's Board of Directors decided to pursue this course of action after a review of the Company's financial position and investment alternatives. The Company expects the stock repurchase program to be accretive to earnings.

"This decision reflects our belief that our common stock is undervalued and does not reflect the intrinsic value of Omnicell, its performance and its prospects," said Randall Lipps, Chairman, President and CEO of Omnicell. "The repurchase program supports our strategic growth initiatives while utilizing available cash to optimize stockholder value. We believe Omnicell operations will continue to generate sufficient cash to make funds available for acquisitions and internal development."

Omnicell also announced that it expects 2008 earnings from operating income will be higher than previously estimated and expects the estimated return on cash investments to be reduced to an average of 3% as a result of recent Federal Reserve rate reductions, which will offset the increases in operating income. After these adjusted estimates, Omnicell reaffirms its previous 2008 earnings forecast of $0.85 to $0.88 per share, excluding stock compensation charges.

The purchases of common stock will be executed periodically as market and business conditions warrant on the open market, in negotiated or block trades, or under a Rule 10b5-1 plan, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading laws. The stock repurchase program does not obligate the Company to repurchase any dollar amount or number of shares of common stock, and the timing and amount of any stock repurchased under the program will depend on market conditions, stock price, corporate and regulatory requirements, capital availability and other factors. Repurchases may be commenced or suspended at any time or from time to time without prior notice.

About Omnicell

Omnicell, Inc. (Nasdaq: OMCL) is a leading provider of systems and software solutions targeting patient safety and operational efficiency in healthcare facilities. Since 1992, Omnicell has worked to enhance patient safety and allow clinicians to spend more time with their patients.

Omnicell's medication-use product line includes solutions for the central pharmacy, nursing unit, operating room, and patient bedside. Solutions range from large central pharmacy "smart inventory" carousels to small handheld devices. From the point at which a medication arrives at the receiving dock to the time it is administered, Omnicell systems store it, package it, bar code it, order it, issue it, and provide information and controls on its use and reorder.

Omnicell's supply product lines provide a healthcare institution with fast, effective control of costs, capture of charges for payer reimbursement, and timely reorder of supplies. Products range from high-security closed-cabinet systems and software to open-shelf and combination solutions in the nursing unit, cath lab and operating room.

Omnicell's mission is to provide the best customer experience in healthcare, helping hospitals reduce medication errors, operate more efficiently, and decrease costs. For more information, visit http://www.omnicell.com.

Forward-Looking Statement

Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements may relate, among other things, to the Company's ability to execute its common stock repurchase program; the Company's expected financial and operating results; its ability to build and grow its business; the benefits or advantages of the stock repurchase program, services, or products; its ability to achieve its goals, plans and objectives; its ability to attract and retain customers; and its acquisition and development activities. As such, they are subject to the occurrence of many events outside Omnicell's control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. The risk factors are described in the caption "Risk Factors" in the Company's Securities and Exchange Commission (SEC) filings. Prospective investors are cautioned not to place undue reliance on forward-looking statements.


'/>"/>
SOURCE Omnicell, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hospital Environments Increase Staff Efficiency and Patient Safety With Omnicell OptiFlex(TM) SS 9.0
2. Omnicell Schedules Fourth Quarter Earnings Call
3. Omnicell Debuts Industrys First Total Automated Patient-Specific Management Solution
4. Omnicell Announces Agreement to Acquire Rioux Vision, Inc.
5. Omnicell to Present at Piper Jaffray 19th Annual Health Care Conference
6. Hendricks Regional Health Increases Patient Safety and Pharmacy Efficiency With Omnicell WorkflowRx 5.0
7. Omnicell Reports Strong Q3 Revenue and Profit Growth
8. Grant Regional Health Center Increases Patient Safety and Pharmacy Efficiency with Omnicell Medication Use Systems
9. Omnicell Schedules Third Quarter Earnings Call
10. Omnicell Introduces the Next Generation Central Pharmacy Automation Solution
11. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology: